One of the largest phase 3 trials of adjuvant bisphosphonate therapy in women with breast cancer has shown that zoledronic acid does not improve overall survival or prevent cancer recurrence. Almost universally, experts called the findings a disappointment. But the study, known as AZURE, has generated a new hypothesis: adjuvant therapy with the bone-building drug may improve survival odds and reduce the risk of disease progression in women with low estrogen levels from natural menopause or medication-induced ovarian suppression.
Graphic Jump Location
Adjuvant therapy with the bisphosphonate zoledronic acid might improve survival in postmenopausal women with breast cancer, according to recent clinical trials.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Table 9.2-2 Refuted Evidence From Studies of Physiologic or Surrogate Endpoints
The Rational Clinical Examination
Make the Diagnosis: Breast Cancer
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.